Drug Delivery of Pegylated Nanoliposomal Cisplatin in Ovarian Cancer Cell Line A2780CP: in vitro Study

Aim & Drug delivery, and using of nanocarriers like pegylated nanoliposomal cisplatin are known as one of the effective method for cancer treatment. In this study, various nanoparticle formulations of cisplatin were prepared and efficacy of the prepared formulations were evaluated in vitro environment.
Reverse phase evaporation technique was used to obtain the pegylated nanoliposomal cisplatin. Cytotoxicity of pegylated nanoliposomal cisplatin were determined in A2780CP ovarian cancer cell lines by using MTT assay. Loading percentage of cisplatin was obtained by inductively coupled plasma spectroscopy.
The mean size, and zeta potential of nanodrug formulations were obtained 100 ± 2.2 nm, and -18.1 ±1.5 mV , respectively. Cytotoxicity of free drug and nanodrug (IC50 values) were estimated 76.6 ± 3.1 µg/mL , and 46.6 ± 2.3 µg/mL in A2780CP ovarian cancer cell lines, respectively.
Results of this study showed that liposomal nanoparticles could be considered as a suitable nanocarrier for cisplatin. It showed that cytotoxicity of nanodrug was increased significantly in comparison to free drug.